BioSpace News Archive

Roivant Sciences, Vivek Ramaswamy’s umbrella company for his family of “Vants,” announced major restructuring that includes a cut of 10 percent of staff and reshuffling of leadership.

Less than a week after floating the idea of offering its experimental ALS therapy NurOwn to patients under the recently-passed Right-to-Try legislation, Israel-based BrainStorm Cell Therapeutics has reversed course.

For the first time ever, Cincinnati Children’s Hospital Medical Center ranks second in the nation among all Honor Roll hospitals in U.S.News and World Report’s 2018-2019 Best Children’s Hospitals ranking.

In the spring of 1871, a young medical student named William Osler picked up a book at hand and read a line that had a great influence on his future – “The most important is to focus on what is clear at hand, instead of what is obscure at distance.”

Clinical response merits initiation of stage 2 of the Phase II combination trial

Leading Sports and Spine Specialist’s E-Book Details Options Available to Back Pain Sufferers

Patrick Baeuerle, Ph.D., a pioneer of T cell engaging therapies and executive partner at life sciences venture firm MPM Capital, will give a keynote presentation about next-generation immuno-oncology therapies from Harpoon Therapeutics, Inc. at the upcoming European Congress on Biotechnology (ECB) on Tuesday, July 3 from 10:30 to 11:00 a.m. CEST in Geneva, Switzerland.

CollPlant announced that it has received grant approval from the Israel Innovation Authority (IIA)

Funding Launches New Center Dedicated to Using Artificial Intelligence and Machine Learning to Treat Cardiovascular Disease

These hospitals are the first in Massachusetts to significantly invest in their care staff and patients with training and resources to safely mobilize patients via Atlas Lift Tech.